Treating cancer from the inside out®
Game-changing therapies at the forefront of innovation in radiopharmaceutical cancer therapy
About
Perspective Therapeutics is on a mission to transform cancer treatment with targeted alpha particle therapy
Perspective Therapeutics is a radiopharmaceutical company dedicated to developing image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer.
Technology
Our radioisotope technology delivers radiation at a cellular level
Our revolutionary Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation directly to cancer cells utilizing high-affinity targeting peptides.
In contrast to conventional radiotherapy, this approach targets more potent alpha particles directly to tumor cells, delivering significantly higher energy at a shorter range. Due to its short half-life, the rapid decay of Pb-212 leads to potentially greater tumor cell killing while avoiding the emergence of resistance and limiting the damage to healthy tissue.
In addition, our image-guided theranostics platform allows physicians to confirm tumor target expression and off-target distribution prior to treatment to assist with patient selection and optimize outcomes.
Perspective Therapeutics uses proprietary targeting peptides conjugated to radioisotopes via a proprietary Pb-specific chelator to image tumors, and then deliver alpha-particle radiopharmaceuticals to attack them on a cellular level.
Therapy
Therapeutic Areas
Pipeline
Oncology pipeline of image-guided alpha-particle radiotherapies
Most programs leverage the chemically matched isotope pair Pb-203/212 conjugated to high-affinity, tumor-specific peptides for image-guided alpha particle cancer therapies.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2+ Tumors |
|
Phase 1/2a updates
throughout 2026
Initiate dosing in 2026 |
|||
| VMT01 (MC1R) |
Melanoma (Imaging & Therapy) Melanoma (Imaging & Therapy) |
|
Initial Phase 1/2a data late 2026
Initial Phase 1/2a data late 2026 |
|||
| PSV359 (FAP-α) |
Solid Tumors | Initial Phase 1/2a data late 2026 | ||||
| PSV594 (CCK2R) |
Solid Tumors | Initiate dosing | ||||
| Multiple (Undisclosed) |
Undisclosed | First in human images | ||||